Sorted By:

Relevance


Programs and Initiatives

PhRMA  |  From PhRMA


https://www.phrma.org/resources/state-map/stem

PPA: Spread the word

PhRMA  |  Blog Post

Learn more at: PPA Website PPA Brochure PPA Video “Spread the Word about PPAPPA Video “PPA Spread the Word 2”  
http://catalyst.phrma.org/ppa-spread-the-word

Pat Scannon, Xoma

From Hope To Cures  |  From Our Network

...
http://www.fromhopetocures.org/video/pat-scannon-xoma

PhRMA Statement on Comments to CMS Regarding Proposed Part D Rule and RFI Exploring Pass-Through Rebates to Seniors at Point of Sale

PhRMA  |  Press Release

Excerpts from comments: “Strong competition among private plans has fueled the Part D program’s success.
https://www.phrma.org/press-release/phrma-statement-on-comments-to-cms-regarding-proposed-part-d-rule-and-rfi-exploring-pass-through-rebates-to-seniors-at-point-of-sale

How drug importation schemes could increase U.S. law enforcement burdens

PhRMA  |  Blog Post

Criminals actively look to skirt law enforcement by mislabeling products and the like.
http://catalyst.phrma.org/how-drug-importation-schemes-could-increase-u.s.-law-enforcement-burdens

Closing the Gap: Increasing Global Competition to Attract and Grow the Biopharmaceutical Sector

PhRMA  |  Report

The biopharmaceutical industry’s economic benefit in the United States is amplified by its large-scale supply chain for research and development (R&D), manufacturing, and distribution activities.
https://www.phrma.org

Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines

PhRMA  |  Blog Post

Learn more about Medicare Part D and the program’s successes, here.
http://catalyst.phrma.org/medicare-monday-same-bad-ideas-continue-to-threaten-part-d-and-beneficiary-access-to-medicines

Chart Pack: Biopharmaceuticals in Perspective

PhRMA  |  Report

Topics include medicines’ impact on health and quality of life, the drug discovery and development process, health care spending and costs, the challenges of addressing treatment gaps and improving the use of prescribed therapies, and the contributions of the biopharmaceutical sector.
https://www.phrma.org

Medicare Monday: Part D premiums expected to drop in 2018

PhRMA  |  Blog Post

We must continue to protect this critical program so seniors and people living with disabilities can continue to live happy, healthy lives.
http://catalyst.phrma.org/part-d-premiums-expected-drop-2018

Ask About Adherence: Private-sector collaboration can lead to savings and care improvement

PhRMA  |  Blog Post

P4HA's report to learn more about how a safe harbor for adherence programs could solve one of America’s most overlooked behavioral health crises.
http://catalyst.phrma.orghttps://catalyst.phrma.org/ask-about-adherence-private-sector-collaboration-can-lead-to-savings-and-care-improvement

Value-Based Contracting for Oncology Drugs: A NEHI White Paper

PhRMA  |  Report

This white paper from the Network for Excellence in Health Innovation (NEHI) outlines barriers to these outcomes-based contracts and highlights regulatory steps that would enable new payment arrangements for high-cost cancer treatments.  
https://www.phrma.org/report/value-based-contracting-for-oncology-drugs-a-nehi-white-paper

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

PhRMA  |  Blog Post

Or they can risk a massive financial penalty that equates legitimate enforcement with patent abuse.
http://catalyst.phrma.org/australia-is-making-it-harder-to-protect-inventions.-thats-bad-for-american-businesses-and-jobs

Part D

PhRMA  |  From PhRMA

For 2016, there are, on average, 26 Part D plan choices available in every region.
https://www.phrma.org/advocacy/medicare/partd

Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation

PhRMA  |  Blog Post

There’s no denying that the talented individuals working within the Bay Area will be at the forefront of game-changing discoveries in our industry, transforming the innovation pipeline as we know it.
http://catalyst.phrma.org/putting-the-bio-in-biotech-how-bay-area-minds-are-powering-biopharmaceutical-innovation

Coverage Gap Phaseout, to Date, Has Improved Medication Adherence for Diabetes

Chartpack  |  From Our Network

Research shows that the phaseout of the coverage gap is making medicines more affordable in the gap and has resulted in patients adhering better to prescribed therapies.
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/coverage-gap-phaseout-to-date-has-improved-medication-adherence-for-diabetes

Guest post: Help celebrate #ChampionsofScience: Nominate a pioneering researcher for the 2018 Dr. Paul Janssen Award for Biomedical Research

PhRMA  |  Blog Post

I encourage you to nominate a researcher whose work has made, or has the potential to make, a meaningful impact on human health.
http://catalyst.phrma.orghttps://catalyst.phrma.org/guest-post-help-celebrate-championsofscience-nominate-a-pioneering-researcher-for-the-2018-dr.-paul-janssen-award-for-biomedical-research

Former law enforcement officials raise concerns with drug importation proposals

PhRMA  |  Blog Post

If the Sanders drug importation bill is passed, the dead may soon include patients who thought they were taking legitimate drugs for legal purposes.”
http://catalyst.phrma.org/former-law-enforcement-officials-raise-concerns-with-drug-importation-proposals

RA medicines often demonstrate far greater benefits to patients than initially understood

PhRMA  |  Blog Post

Unlike the Institute for Clinical and Economic Review, which recently undertook an assessment of RA treatments, we need approaches to value assessments that can keep pace with changes in research and treatment options over time.
http://catalyst.phrma.org/ra-medicines-often-demonstrate-far-greater-benefits-to-patients-than-initially-understood

PhRMA Statement on House Vote to Repeal IPAB

PhRMA  |  Press Release

“It is long past time that Congress took action to protect America’s seniors by repealing IPAB, and there has been strong bipartisan support from members of Congress and broad support from stakeholders across the health care sector to eliminate this dangerous Board.
https://www.phrma.org/press-release/phrma-statement-on-house-vote-to-repeal-ipab

Medicare Monday: Medicare Part D by the numbers

PhRMA  |  Blog Post

And another recent study found that mortality rates for the elderly have decreased every year since the Part D program was implemented in 2006. 
http://catalyst.phrma.org/medicare-monday-medicare-part-d-by-the-numbers

Executive Assistant – Law Department

PhRMA  |  PhRMA Career

Send resume and salary requirement for consideration to: jobs@phrma.org      
https://www.phrma.org

Site Map

PhRMA  |  From PhRMA

...
https://www.phrma.org/site-map

PPA Celebrates Fourth Anniversary Has Helped More Than 5.7 Million Uninsured Patients

PhRMA  |  Press Release

It only takes 10 to 15 minutes to find out if someone may qualify for free or discounted medications.
https://www.phrma.org/press-release/ppa-celebrates-fourth-anniversary-has-helped-more-than-5-7-million-uninsured-patients

Phaseout of Coverage Gap in Part D Began in 2011

Chartpack  |  From Our Network

Beginning in 2011, beneficiaries receive a 50% discount on brand drugs while in the coverage gap, at a cost to brand manufacturers of $41 billion over 10 years (2012-2021).
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/phaseout-of-coverage-gap-in-part-d-began-in-2011

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

PhRMA  |  Blog Post

As part of its effort to modernize NAFTA, the U.S. should seek to ensure stronger enforcement of patentability standards and the provisions that protect the IP of U.S. innovators, as well as address potentially negative price-setting measures.
http://catalyst.phrma.org/as-u.s.-looks-to-modernize-nafta-strong-enforcement-of-existing-obligations-should-be-a-top-priority

You have reviewed the first 50 results out of 2221. Each page contains 25 results. You're on page 2.

prev 1 2 3 4 5 6 next